Clinical Trials Directory

Trials / Completed

CompletedNCT02437344

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
16 (actual)
Sponsor
New York State Psychiatric Institute · Academic / Other
Sex
All
Age
21 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Opioid dependence is a substantial problem associated with significant morbidity and mortality. Extended-release naltrexone has been found effective at reducing opioid use and maintaining abstinence, but its use has been limited by the difficulties encountered with treatment initiation, which involves detoxification from opioids and oral naltrexone titration. Improving the likelihood of a successful transition to naltrexone is therefore an important public health goal. N-methyl-D-aspartate receptor (NMDA) antagonism has been found to alleviate the signs and symptoms of withdrawal from opioids, as well as to address adaptations associated with chronic opioid use, such as opioid-induced hyperalgesia (increased pain sensitivity). These benefits may persist for at least 72 hours after a single dose. NMDA antagonism may therefore facilitate a rapid transition to naltrexone by reducing discomfort, improving motivation, and ameliorating adaptations associated with drug dependence, such as craving and arousal. The purpose of this trial is to assess the feasibility of NMDA antagonist-assisted naltrexone initiation in opioid dependent individuals. After administration of extended-release naltrexone, participants will be followed for 4 weeks, and transitioned to appropriate care subsequently (oral naltrexone, extended-release naltrexone).

Conditions

Interventions

TypeNameDescription
DRUGCI-581aa92 minute infusion of CI-581aa
DRUGNaltrexone titration and XR-NTX initiationparticipants will be provided a titration of naltrexone that culminates in the injection of XR-NTX

Timeline

Start date
2015-01-01
Primary completion
2016-12-01
Completion
2016-12-01
First posted
2015-05-07
Last updated
2019-04-08
Results posted
2017-09-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02437344. Inclusion in this directory is not an endorsement.